Misplaced Pages

Tenatoprazole

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Tenatoprazole
Clinical data
Routes of
administration		Oral
ATC code
  • none
Pharmacokinetic data
MetabolismHepatic (CYP2C19-mediated)
Elimination half-life4.8 to 7.7 hours
Identifiers
IUPAC name
  • 5-methoxy-2--1H-imidazopyridine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.120.697 Edit this at Wikidata
Chemical and physical data
FormulaC16H18N4O3S
Molar mass346.41 g·mol
3D model (JSmol)
ChiralityRacemic mixture
SMILES
  • Cc1c(OC)c(C)cnc1CS(=O)c2c3ccc(OC)nc3n2
InChI
  • InChI=1S/C16H18N4O3S/c1-9-7-17-12(10(2)14(9)23-4)8-24(21)16-18-11-5-6-13(22-3)19-15(11)20-16/h5-7H,8H2,1-4H3,(H,18,19,20)
  • Key:ZBFDAUIVDSSISP-UHFFFAOYSA-N
  (verify)

Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003. The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007).

Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007 and again in 2012.

Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.

See also

References

  1. "Gastrointestinal Disease Update". Digestive Disease Week. DataMonitor. March 2003.
  2. "Investors unwilling to forgive Wockhardt, promoter for failings". Economic Times. 3 March 2011. Archived from the original on November 16, 2014.
  3. ^ "State of New Product Development" (PDF). Mitsubishi Tanabe Pharma. 8 May 2012.
  4. "FY2007 Interim Financial Results". Mitsubishi Tanabe Pharma.
  5. Li H, Meng L, Liu F, Wei JF, Wang YQ (January 2013). "H+/K+-ATPase inhibitors: a patent review". Expert Opinion on Therapeutic Patents. 23 (1): 99–111. doi:10.1517/13543776.2013.741121. PMID 23205582. S2CID 44647770.
Drugs for peptic ulcer and GERD/GORD (A02B)
H2 antagonists ("-tidine")
Prostaglandins (E)/
analogues ("-prost-")
Proton-pump inhibitors
("-prazole")
Potassium-competitive
acid blockers ("-prazan")
Others
Combinations
Categories: